Teleflex Incorporated
TFXHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframeTeleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications in the. With a market capitalization of $5.96B, it sits in mid-cap territory. The company offers vascular and emergency medicine products comprising Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous bone access systems for the administration of intravenous therapies, measurement of blood pressure, and collection of blood samples; intraosseous access systems consisting of EZ-IO intraosseous vascular access systems, and Arrow FAST1 sternal intraosseous infusion systems; and hemostatic products, including external hemostats and trauma products under the QuikClot brand.
Market Cap
$5.96B
Beta
0.82
P/E (TTM)
2692.20
P/E (Fwd)
12.72
EPS (TTM)
$0.05
EPS (Fwd)
$10.58
ROE
0.0%
ROA
2.3%
Cash
$333.1M
Total Debt
$2.74B
Free CF
-$3.7M
52W Change
21.2%
Annual Financials
Cash vs Debt
On the balance sheet, TFX has $333.1M in cash with $2.74B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company is burning cash, with free cash flow at -$3.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of 0.0% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 2.3% is on the lower side, which is common in asset-heavy industries. Revenue has pulled back from $2.79B (2022) to $1.99B (2025), a 29% decline worth watching.
Teleflex Incorporated carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing TFX.